Patents Assigned to Amgen
  • B7 related protein-2 molecules and uses thereof
    Publication number: 20030039999
    Abstract: The present invention provides B7 Related Protein-2 (B7RP-2) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7RP-2 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7RP-2 polypeptides.
    Type: Application
    Filed: May 28, 2002
    Publication date: February 27, 2003
    Applicant: Amgen, Inc.
    Inventors: Steven Kiyoshi Yoshinaga, Woong-Kyung Suh, Tak Wah Mak
  • Apo-AI/AII peptide derivatives
    Publication number: 20030040470
    Abstract: The present invention concerns therapeutic agents that mimic the activity of Apo-AI amphipathic helix peptide.
    Type: Application
    Filed: April 23, 2001
    Publication date: February 27, 2003
    Applicant: Amgen Inc.
    Inventor: Tadahiko Kohno
  • Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
    Publication number: 20030039654
    Abstract: The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP.
    Type: Application
    Filed: April 26, 2001
    Publication date: February 27, 2003
    Applicant: Amgen Inc.
    Inventors: Paul Kostenuik, Chuan-Fa Liu, David Lee Lacey
  • Fhm, a novel member of the TNF ligand supergene family
    Patent number: 6521422
    Abstract: The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: February 18, 2003
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Scott Kenneth Wooden, William James Boyle
  • Glucagon antagonists
    Publication number: 20030032588
    Abstract: The present invention concerns therapeutic agents that antagonize the activity of glucagon.
    Type: Application
    Filed: May 2, 2001
    Publication date: February 13, 2003
    Applicant: Amgen Inc.
    Inventors: William S. Marshall, Kevin Lee Stark
  • Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
    Publication number: 20030026806
    Abstract: The invention concerns methods of treating IL-1-mediated disease by administering a selective IL-1 binding agents that form an antagonist complex with the IL-1 ligand. The antagonist complex can bind to the IL-1 receptor without activating the receptor. The selective binding agents contemplated by this invention thus have the properties of free ligand absorption (through binding of the selective binding agent to free IL-1&agr; or &bgr;) and receptor activation inhibition (through binding of the antagonist complex to the receptor and preventing its activation).
    Type: Application
    Filed: October 29, 2001
    Publication date: February 6, 2003
    Applicant: Amgen Inc.
    Inventors: Alison Witte, Brian C. Varnum, Xueming Qian, Chris Vezina
  • Fused cycloheptane and fused azacycloheptane compounds and their methods of use
    Patent number: 6514964
    Abstract: The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as &agr;v&bgr;3, &agr;v&bgr;5, &agr;v&bgr;6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: February 4, 2003
    Assignee: Amgen Inc.
    Inventors: Zhidong Chen, Celia Dominguez, Ellen Grenzer-Laber, Nianhe Han, Longbing Liu, Ofir A. Moreno, Melvin C. Rutledge, Andrew S. Tasker
  • Chemical modification of proteins to improve biocompatibility and bioactivity
    Publication number: 20030023048
    Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
    Type: Application
    Filed: May 6, 2002
    Publication date: January 30, 2003
    Applicant: Amgen Inc.
    Inventors: Colin Gegg, Olaf Kinstler
  • Interleukin-1&bgr; converting enzyme like cysteine protease
    Patent number: 6512104
    Abstract: A new member of a family of ICE-like cysteine proteases has been identified. The protease family is termed LICE (Like ICE) and the family member described herein is LICE3. LICE3 polypeptides, nucleic acids encoding LICE3 and vectors and host cells for the expression LICE3 are disclosed. Also disclosed are methods for identifying LICE3 agonists and antagonists, and methods for treatment of disorders characterized by altered apoptosis.
    Type: Grant
    Filed: October 1, 1996
    Date of Patent: January 28, 2003
    Assignee: Amgen Inc.
    Inventors: Shao-Chieh Juan, Frederick A. Fletcher, Scott D. Patterson
  • Methods and compositions for preparing a genomic library for knockout targeting vectors
    Patent number: 6503712
    Abstract: The present invention is directed to methods for producing gene targeting constructs by homologous recombination using mouse genomic libraries arrayed in yeast shuttle vectors. The invention is also directed to methods of using targeting constructs made by the methods to generate transgenic animals.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: January 7, 2003
    Assignee: Amgen Inc.
    Inventor: Sushil K. Thukral
  • Interleukin-1 receptor antagonist-related molecules and uses thereof
    Publication number: 20030004106
    Abstract: The present invention provides novel Interleukin-1 Receptor Antagonist-Related (IL-1ra-R) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IL-1ra-R polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IL-1ra-R polypeptides.
    Type: Application
    Filed: May 6, 2002
    Publication date: January 2, 2003
    Applicant: Amgen, Inc., A Corporation of the State of Delaware
    Inventors: Christiaan M. Saris, Jennifer Giles, Sharon X. Mu, Min Xia, Michael Brian Bass, Roger Craveiro
  • Human collagenase inhibitor, recombinant vector system for using same and recombinant DNA method for the manufacture of same
    Publication number: 20030003556
    Abstract: A portable DNA sequence is disclosed which is capable of directing intracellular production of metalloproteinanse inhibitors. Vectors containing this portable DNA sequence are also set forth, including the vector pUC9-F5/237P10 (ATCC Accession No. 53003). A recombinant-DNA method for the microbial production of a metalloproteinase inhibitor, which method incorporates at least one of the portable DNA sequences and the vectors disclosed herein.
    Type: Application
    Filed: November 14, 2001
    Publication date: January 2, 2003
    Applicant: AMGEN INC.
    Inventors: David F. Carmichael, David C. Anderson, George P. Stricklin, Howard G. Welgus
  • Antibodies against analogs of brain-derived neurotrophic factor
    Patent number: 6500429
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: December 31, 2002
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Glial cell line-derived neurotrophic factor
    Publication number: 20020197675
    Abstract: A novel neurotrophic factor referred to as glial derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Application
    Filed: November 13, 2001
    Publication date: December 26, 2002
    Applicant: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Kinase inhibitors
    Patent number: 6495558
    Abstract: The invention relates to inhibitors of kinases, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods for treating disease or disease symptoms.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: December 17, 2002
    Assignee: Amgen Inc.
    Inventors: David M. Armistead, Jean E. Bemis, Daniel Elbaum, Gregory J. Habgood, Perry M. Novak, Joseph J. Nunes, Leticia M. Toledo-Sherman
  • Polynucleotides encoding a novel SHC-binding protein
    Patent number: 6492138
    Abstract: Novel Shc-binding protein, oligonucleotides encoding the same, methods of producing and use thereof are disclosed.
    Type: Grant
    Filed: May 21, 1998
    Date of Patent: December 10, 2002
    Assignee: Amgen Canada Inc.
    Inventors: Jane McGlade, Rosemary Schmandt
  • Chemically-modified G-CSF
    Publication number: 20020177688
    Abstract: The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: 1                                       (Met) n Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln   Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg   Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu   Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro   Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly   Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser   Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln   Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu  
    Type: Application
    Filed: August 2, 2001
    Publication date: November 28, 2002
    Applicant: Kirin-Amgen, Inc.,
    Inventors: Rika Ishikawa, Yuji Okada, Makoto Kakitani
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020169118
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: November 14, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Integrin/adhesion antagonists
    Publication number: 20020168363
    Abstract: The present invention concerns fusion of half-life extending vehicles, preferably Fc domains, with peptide sequences that act as antagonists of integrins, selectins, cell adhesion molecules, or their respective receptors. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The peptide may be an existing peptide or a peptide selected by phage display, E. coli display, ribosome display, RNA-peptide screening, chemical-peptide screening, or other methods.
    Type: Application
    Filed: April 23, 2001
    Publication date: November 14, 2002
    Applicant: Amgen Inc.
    Inventors: Ulrich Feige, Tadahiko Kohno, David Lee Lacey, Thomas Charles Boone
  • Eck receptor ligands
    Patent number: 6479250
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: November 12, 2002
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker